StockData
OnKure Therapeutics, Inc. logo

OnKure Therapeutics, Inc. (OKUR) stock

OKURNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/30
$2.58−0.17 (-6.18%)

Close on Nov 17, 2026Market cap $104.48MP/E –Yield –

OnKure Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

OnKure Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $46.95M, down 6.3% year over year. For fiscal 2025 it was $48.26M, up 10.2% from the year before. The highest annual figure on record is $48.26M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$48.26M+10.2%
FY2024Dec 31, 2024$43.80M+36.4%
FY2023Dec 31, 2023$32.12M-14.8%
FY2022Dec 31, 2022$37.71M+33.9%
FY2021Dec 31, 2021$28.17M+76.7%
FY2020Dec 31, 2020$15.94M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$12.61M-0.0%
Q1 FY2026Mar 31, 2026$11.71M-10.0%
Q4 FY2025Dec 31, 2025$10.72M-25.4%
Q3 FY2025Sep 30, 2025$11.92M+17.8%
Q2 FY2025Jun 30, 2025$12.61M+17.3%
Q1 FY2025Mar 31, 2025$13.01M+51.9%
Q4 FY2024Dec 31, 2024$14.36M-18.4%
Q3 FY2024Sep 30, 2024$10.12M-25.7%
Q2 FY2024Jun 30, 2024$10.75M-25.3%
Q1 FY2024Mar 31, 2024$8.57M-22.1%
Q4 FY2023Dec 31, 2023$17.60M+70.0%
Q3 FY2023Sep 30, 2023$13.62M+37.1%
Q2 FY2023Jun 30, 2023$14.40M+77.1%
Q1 FY2023Mar 31, 2023$10.99M+18.5%
Q4 FY2022Dec 31, 2022$10.36M+45.9%
Q3 FY2022Sep 30, 2022$9.94M+6.7%
Q2 FY2022Jun 30, 2022$8.13M+29.5%
Q1 FY2022Mar 31, 2022$9.28M+69.6%
Q4 FY2021Dec 31, 2021$7.10M+38.7%
Q3 FY2021Sep 30, 2021$9.32M+110.3%
Q2 FY2021Jun 30, 2021$6.28M+122.9%
Q1 FY2021Mar 31, 2021$5.47M+52.9%
Q4 FY2020Dec 31, 2020$5.12M–
Q3 FY2020Sep 30, 2020$4.43M–
Q2 FY2020Jun 30, 2020$2.82M–
Q1 FY2020Mar 31, 2020$3.58M–

More OnKure Therapeutics figures

See a number that looks wrong?